Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2014

01-10-2014 | Original Article

Health-related quality of life and prognosis in patients with chronic kidney disease: a 3-year follow-up study

Authors: Reiko Okubo, Hirayasu Kai, Masahide Kondo, Chie Saito, Keigyou Yoh, Naoki Morito, Joichi Usui, Kunihiro Yamagata

Published in: Clinical and Experimental Nephrology | Issue 5/2014

Login to get access

Abstract

Background

Chronic kidney disease (CKD) is a major global problem and is also associated with a decreased health-related quality of life (HRQOL). The aim of this study was to evaluate measured HRQOL based on the new CKD classification including proteinuria stage, and the effect of measured HRQOL on CKD progression and clinical outcomes over a 3-year period.

Methods

EuroQol (EQ-5D), a generic preference-based questionnaire, was administered to 537 CKD outpatients at the University of Tsukuba Hospital between November and December 2008. We evaluated disease progression in CKD patients including the incidence of end-stage kidney disease (ESKD), cardiovascular disease (CVD) and all-cause mortality over a 3-year follow-up period.

Results

The proportions progressing to the higher stages were 32.6, 20.0, 36.6, 39.5, and 45.8 % from glomerular filtration rate (GFR) stages (G) 1–4, respectively. The proportion progressing to ESKD (G5D) was 0.7 % from G2, 3.9 % from G3b, 20.8 % from G4 and 63.4 % from G5. The incidence of CVD and/or death was 1.2, 4.6, 4.9, 5.3, 8.3 and 21.1 % from G1−G5, respectively. The quality-adjustment weights at G4–5 were significantly lower than at G1–2 and the weights at proteinuria stage (A) 3 were significantly lower than at A1–2. The quality-adjustment weights of patients with events such as 50 % estimated GFR decline, dialysis, CVD, and/or death were significantly lower than those without events.

Conclusion

We showed CKD progression and clinical outcomes over a 3-year period. Quality-adjustment weights in CKD patients were associated with not only disease progression such as initiation of dialysis treatment and incidence of CVD events and all-cause death, but also the level of proteinuria at baseline.
Literature
1.
go back to reference Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–63.PubMedCrossRef Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–63.PubMedCrossRef
2.
go back to reference Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef
3.
go back to reference Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec 31, 2011. Tokyo: Japanese Society for Dialysis Treatment; 2012 (in Japanese). Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec 31, 2011. Tokyo: Japanese Society for Dialysis Treatment; 2012 (in Japanese).
4.
go back to reference Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.PubMedCrossRef Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.PubMedCrossRef
5.
go back to reference Finkelstein FO, Wuerth D, Finkelstein SH. Health related quality of life and the CKD patient: challenges for the nephrology community. Kidney Int. 2009;76(9):946–52.PubMedCrossRef Finkelstein FO, Wuerth D, Finkelstein SH. Health related quality of life and the CKD patient: challenges for the nephrology community. Kidney Int. 2009;76(9):946–52.PubMedCrossRef
6.
go back to reference Mujais SK, Story K, Brouillette J, et al. Health-related quality of life in CKD Patients: correlates and evolution over time. Clin J Am Soc Nephrol. 2009;4:1293–301.PubMedCrossRefPubMedCentral Mujais SK, Story K, Brouillette J, et al. Health-related quality of life in CKD Patients: correlates and evolution over time. Clin J Am Soc Nephrol. 2009;4:1293–301.PubMedCrossRefPubMedCentral
7.
go back to reference Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;45:658–66.PubMedCrossRef Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;45:658–66.PubMedCrossRef
8.
go back to reference Chow FY, Briganti EM, Kerr PG, et al. Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis. 2003;41:596–604.PubMedCrossRef Chow FY, Briganti EM, Kerr PG, et al. Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis. 2003;41:596–604.PubMedCrossRef
9.
go back to reference Pagels AA, Söderkvist BK, Medin C, et al. Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health Qual Life Outcomes. 2012;10:71.PubMedCrossRefPubMedCentral Pagels AA, Söderkvist BK, Medin C, et al. Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health Qual Life Outcomes. 2012;10:71.PubMedCrossRefPubMedCentral
10.
go back to reference Team Japanese EuroQol Translation. The development of the Japanese EuroQol instrument. J Health Care Soc. 1997;8:109–23 (in Japanese). Team Japanese EuroQol Translation. The development of the Japanese EuroQol instrument. J Health Care Soc. 1997;8:109–23 (in Japanese).
11.
go back to reference Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341–53.PubMedCrossRef Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341–53.PubMedCrossRef
12.
go back to reference Tajima R, Kondo M, Kai H, et al. Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clin Exp Nephrol. 2010;14:340–8.PubMedCrossRef Tajima R, Kondo M, Kai H, et al. Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clin Exp Nephrol. 2010;14:340–8.PubMedCrossRef
13.
go back to reference Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.PubMedCrossRef Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.PubMedCrossRef
14.
go back to reference Hemmelgarn BR, Zhang J, Manns B, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006;69:2155–61.PubMedCrossRef Hemmelgarn BR, Zhang J, Manns B, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006;69:2155–61.PubMedCrossRef
15.
go back to reference Kelley K, Aricak OT, Light RP, et al. Proteinuria is a determinant of quality of life in diabetic nephropathy: modeling lagged effects with path analysis. Am J Nephrol. 2007;27:488–94.PubMedCrossRef Kelley K, Aricak OT, Light RP, et al. Proteinuria is a determinant of quality of life in diabetic nephropathy: modeling lagged effects with path analysis. Am J Nephrol. 2007;27:488–94.PubMedCrossRef
16.
go back to reference Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRef Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRef
17.
go back to reference Nakayama M, Sato T, Sato H, et al. Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: Gonryo study. Clin Exp Nephrol. 2010;14:333–9.PubMedCrossRef Nakayama M, Sato T, Sato H, et al. Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: Gonryo study. Clin Exp Nephrol. 2010;14:333–9.PubMedCrossRef
18.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evidence, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evidence, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
19.
go back to reference Yamashita T, Yoshida T, Ogawa T, et al. Clinical outcomes in patients with chronic kidney disease: a 5-year retrospective cohort study at a University Hospital in Japan. Clin Exp Nephrol. 2011;15:831–40.PubMedCrossRef Yamashita T, Yoshida T, Ogawa T, et al. Clinical outcomes in patients with chronic kidney disease: a 5-year retrospective cohort study at a University Hospital in Japan. Clin Exp Nephrol. 2011;15:831–40.PubMedCrossRef
20.
go back to reference Hanratty R, Chonchol M, Miriam Dickinson L, et al. Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrol Dial Transplant. 2010;25:801–7.PubMedCrossRefPubMedCentral Hanratty R, Chonchol M, Miriam Dickinson L, et al. Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrol Dial Transplant. 2010;25:801–7.PubMedCrossRefPubMedCentral
21.
go back to reference Gansevoort RT, Matsushita K, van der Velde M, et al. Chronic Kidney Disease Prognosis Consortium: lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93–104.PubMedCrossRefPubMedCentral Gansevoort RT, Matsushita K, van der Velde M, et al. Chronic Kidney Disease Prognosis Consortium: lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93–104.PubMedCrossRefPubMedCentral
22.
go back to reference Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.CrossRef Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.CrossRef
Metadata
Title
Health-related quality of life and prognosis in patients with chronic kidney disease: a 3-year follow-up study
Authors
Reiko Okubo
Hirayasu Kai
Masahide Kondo
Chie Saito
Keigyou Yoh
Naoki Morito
Joichi Usui
Kunihiro Yamagata
Publication date
01-10-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0901-x

Other articles of this Issue 5/2014

Clinical and Experimental Nephrology 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine